Want to see BAYRY full AI Analyst Report?
EBITDA Margin by Segment
Measures the profitability of each segment as a percentage of revenue, offering insight into cost management and pricing power across different areas of the business.Bayer's Crop Science segment shows significant volatility, with recent declines suggesting operational challenges or market pressures. Meanwhile, the Pharmaceutical segment's margins have softened since 2023, indicating potential competitive or pricing pressures. Consumer Health remains relatively stable, suggesting resilience in consumer demand. The absence of earnings call commentary leaves uncertainty about strategic responses to these trends, but the data suggests a need for Bayer to address volatility in Crop Science and margin pressures in Pharmaceuticals to sustain profitability.
Date | Crop Science | Pharmaceutical | Consumer Health |
|---|---|---|---|
Mar 31, 2025 | 33.70 | 29.50 | 22.80 |
Dec 31, 2024 | 17.00 | 23.70 | 23.00 |
Sep 30, 2024 | 0.90 | 24.40 | 25.50 |
Jun 30, 2024 | 10.50 | 28.70 | 21.50 |
Mar 31, 2024 | 36.00 | 27.40 | 23.10 |
Dec 31, 2023 | 19.00 | 27.60 | 24.30 |
Sep 30, 2023 | -0.50 | 31.70 | 22.20 |
Jun 30, 2023 | 14.70 | 30.30 | 22.90 |
Mar 31, 2023 | 39.10 | 25.10 | 24.10 |
Dec 31, 2022 | 14.70 | 29.50 | 20.50 |